RECRUITINGOBSERVATIONAL

Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in Belgium

Understanding Local TReatment Patterns and Outcomes With upAdacitinib in IBD Patients in Belgium

About This Trial

Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. Ulcerative colitis (UC) is an idiopathic, chronic, inflammatory disease affecting the colon. This study will assess the (long-term) effectiveness and safety of upadacitinib in real-world clinical practice in adult participants with moderate to severe ulcerative colitis (UC) and crohn's disease (CD). Upadacitinib is an approved drug for treating ulcerative colitis (UC) and Crohn's disease (CD). Approximately 280 participants who are prescribed Upadacitinib by their physician in accordance with local label will be enrolled in 8 sites across Belgium. Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 3 years. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice

Who May Be Eligible (Plain English)

Who May Qualify: - Participants with a diagnosis of moderate to severe Crohn's disease or Ulcerative colitis, initiated with upadacitinib at least 12 months prior to inclusion, including participants that were initiated on upadacitinib, but later (i.e. at the moment of data collection) discontinued, or switched to another treatment. - Participants initiating commercially available upadacitinib at the clinician's discretion as part of their routine clinical care; the decision to administer upadacitinib must be made prior to and independent of recruitment into the study - Participants prescribed upadacitinib in accordance with the approved local label and treatment recommendations Who Should NOT Join This Trial: - Participants previously exposed to upadacitinib in a clinical trial or early access program - Participants participating in interventional research (not including non-interventional - Participants with stoma Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Participants with a diagnosis of moderate to severe Crohn's disease or Ulcerative colitis, initiated with upadacitinib at least 12 months prior to inclusion, including participants that were initiated on upadacitinib, but later (i.e. at the moment of data collection) discontinued, or switched to another treatment. * Participants initiating commercially available upadacitinib at the clinician's discretion as part of their routine clinical care; the decision to administer upadacitinib must be made prior to and independent of recruitment into the study * Participants prescribed upadacitinib in accordance with the approved local label and treatment recommendations Exclusion Criteria: * Participants previously exposed to upadacitinib in a clinical trial or early access program * Participants participating in interventional research (not including non-interventional * Participants with stoma

Locations (7)

Imelda Ziekenhuis /ID# 268631

Bonheiden, Antwerpen, Belgium

Universite Libre de Bruxelles - Hopital Erasme /ID# 268632

Anderlecht, Brussels Capital, Belgium

CHU de Liège /ID# 267209

Liège, Liege, Belgium

UZ Gent /ID# 268630

Ghent, Oost-Vlaanderen, Belgium

Vitaz /Id# 268637

Sint-Niklaas, Oost-Vlaanderen, Belgium

AZ Groeninge /ID# 268638

Kortrijk, West-Vlaanderen, Belgium

Groupe Sante CHC - Clinique du MontLegia /ID# 268662

Liège, Belgium